Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Market Closed 06-12 16:00:00 EDT

1.10

-0.03

-2.65%

盘后1.10

+0.000.00%

18:26 EDT

High1.17	Low1.04	Vol423.51K
Open1.15	D1 Closing1.13	Amplitude11.45%
Mkt Cap139.70M	Tradable Cap75.66M	Total Shares127.00M
T/O462.39K	T/O Rate0.62%	Tradable Shares68.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":1.1,"timestamp":1781294400000,"preClose":1.13,"halted":0,"volume":423514,"hourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"18:26 EDT","volume":9,"amount":9.96,"timestamp":1781303201176,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02654867256637151,"floatShares":68779500,"shares":127000000,"eps":-0.155821,"marketStatus":"Market Closed","change":-0.03,"latestTime":"06-12 16:00:00 EDT","open":1.15,"high":1.1694,"low":1.04,"amount":462388.09595159994,"amplitude":0.114513,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.155821,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":1.13,"preHourTrading":{"tag":"盘前","latestPrice":1.15,"preClose":1.13,"latestTime":"08:43 EDT","volume":21,"amount":24.15,"timestamp":1781268237369,"change":0.02,"changeRate":0.017699,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.1,"preClose":1.1,"latestTime":"18:26 EDT","volume":9,"amount":9.96,"timestamp":1781303201176,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.5891278553973187,"impliedVol":1.1411,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2637881342","title":"Tiziana Life Sciences’ COO and CFO Keeren Shah files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2637881342","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637881342?lang=en_us&edition=fundamental","pubTime":"2026-05-23 04:56","pubTimestamp":1779483365,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences Chief Operating & Financial Officer Keeren Shah filed an initial beneficial ownership statement reporting 2,500 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL2hx8Pw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637330249","title":"Tiziana Life Sciences Completes Patient Enrollment for Phase 2a Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637330249","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637330249?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:39","pubTimestamp":1779377993,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences  has completed patient enrollment for the phase 2a clinical trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis.The trial enrolled 48 patients in the US who will receive one of two doses of intranasal foralumab or placebo over a 12-week period, to be followed by a six-month open label extension phase, the company said.Topline data from the trial is expected in late Q3, Tiziana added.Price: 1.73, Change: +0.12, Percent Change: +7.45","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637330303","title":"Tiziana fully enrolls Phase 2 placebo-controlled MS trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637330303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637330303?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:05","pubTimestamp":1779375909,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-fully-enrolls-phase-2-placebo-controlled-ms-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-fully-enrolls-phase-2-placebo-controlled-ms-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1791710400.SGD","LU2023251221.USD","BK4516","LU0320765646.SGD","BK4585","LU1244550494.USD","LU0225283273.USD","LU2111349929.HKD","LU1989772923.USD","LU1244550577.SGD","LU2357305700.SGD","LU0528227936.USD","LU1363072403.SGD","LU1732799900.SGD","LU0795875169.SGD","BK4588","LU0053666078.USD","LU1064131342.USD","LU1548497426.USD","LU0882574139.USD","LU0971096721.USD","LU0267386448.USD","LU2089283258.USD","LU2089284900.SGD","BK4127","LU0314104364.USD","LU0390134368.USD","BK4139","LU2133065610.SGD","LU1162221912.USD","LU1988902786.USD","IE00BZ1G4Q59.USD","LU2271345857.HKD","BK4504","BK4534","LU0158827781.USD","LU0158827948.USD","LU1668664300.SGD","LU1720051108.HKD","TLSA","IE00BKVL7J92.USD","LU0098860793.USD","LU0234570918.USD","LU0795875086.SGD","LU2264538146.SGD","LU2028103732.USD","BK4581","LU0106261372.USD","LU1244550221.USD","LU0106831901.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637967337","title":"Tiziana completes enrollment in Phase 2a intranasal foralumab trial in secondary progressive MS","url":"https://stock-news.laohu8.com/highlight/detail?id=2637967337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637967337?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:00","pubTimestamp":1779375632,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences completed patient enrollment in a randomized, double-blind, placebo-controlled Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis.Topline results are expected in late Q3 2026, with data slated for presentation at the ACTRIMS-ECTRIMS meeting in October 2026.The study is designed to assess whether the therapy can reduce neuroinflammation and translate into clinical benefit, addressing a segment with limited treatment options.The trial enrolled 48 patients across U.S. sites, testing two dose levels versus placebo over 12 weeks, followed by an open-label extension intended to support longer-term safety and durability.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLnsl1N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4139","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","BK4588","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","IE00BN0W2T93.GBP","TLSA","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637733754","title":"Tiziana Fully Enrolls Its Phase 2 Placebo Controlled Multiple Sclerosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637733754","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637733754?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:00","pubTimestamp":1779375600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA6F8BCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636865778","title":"Sector Update: Healthcare Stocks Rise Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2636865778","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636865778?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:02","pubTimestamp":1779213753,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) incre","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0689472784.USD","JPMO","LU0234572021.USD","IE0009355771.USD","LABU","LU2054465674.USD","LU1718418525.SGD","LU2505996509.AUD","IE00BWXC8680.SGD","IE0034235295.USD","JPO","LU0266013472.USD","LU0149725797.USD","LU2237443978.SGD","BSX","XLV","BK4516","LU0203345920.USD","LU2746668974.SGD","LU0106261372.USD","LU2746668461.USD","XBI","BSX.AU","LU0353189763.USD","BK4550","IBB","IE00B1XK9C88.USD","LU1670627923.USD","BK4139","LU2265009873.SGD","MTVA","LU0640476718.USD","IE00BJTD4N35.SGD","LU2023250843.SGD","LU1057294990.SGD","LU2362541513.USD","LU1244550494.USD","LU2552382058.USD","HCSG","LU1791710582.SGD","JPX","LU1989772840.SGD","LU2491049909.HKD","IE00B4R5TH58.HKD","LU0208291251.USD","BK4585","BK4581","TLSA","LU0203347892.USD","RLAY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856984","title":"Tiziana Life Sciences announces updated intranasal foralumab data","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856984","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856984?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:13","pubTimestamp":1779192808,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced updated clinical data from its ongoing expanded access program evaluating intranasal foralumab in 14 patient...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-updated-intranasal-foralumab-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-sciences-announces-updated-intranasal-foralumab-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855307","title":"Tiziana Life Sciences Says Multiple Sclerosis Therapy Shows Tolerability, Fatigue Improvement in Updated Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855307","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855307?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:51","pubTimestamp":1779191517,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences'  intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the biotechnology company said Tuesday.Multiple sclerosis is an autoimmune condition of the central nervous system.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636938858","title":"Tiziana reports positive expanded-access data for intranasal foralumab in non-active SPMS","url":"https://stock-news.laohu8.com/highlight/detail?id=2636938858","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636938858?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:00","pubTimestamp":1779188451,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences released updated clinical data from its ongoing expanded-access program of intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis, covering results first presented in March 2025 through March 2026.The update showed the treatment remained well tolerated over longer use, with no new safety concerns flagged.Patients showed favorable trends toward stabilizing disability, with many also reporting clinically meaningful improvements in fatigue.The company framed the findings as supportive of further development, while noting the small expanded-access dataset limits the strength of conclusions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL62zv5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","TLSA","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858989","title":"Tiziana Life Sciences Ltd - Foralumab Well Tolerated With No New Safety Signals Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636858989?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:00","pubTimestamp":1779188400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUASFM8S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636785862","title":"Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2636785862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636785862?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:00","pubTimestamp":1779188400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUASFM8S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636623858","title":"Tiziana Life Sciences Ltd - Intranasal Foralumab Well Tolerated Over Extended Treatment as of March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636623858","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636623858?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:00","pubTimestamp":1779188400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUASFM8S:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635743428","title":"Tiziana Phase 2 trial for foralumab shows reduced brain inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635743428","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635743428?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:46","pubTimestamp":1778766365,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announced initial quantitative PET imaging results from the first two patients with Multiple System Atrophy in a Phase...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-phase-2-trial-for-foralumab-shows-reduced-brain-inflammation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-phase-2-trial-for-foralumab-shows-reduced-brain-inflammation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632297640","title":"Tiziana FY25 net loss widens to USD 18.4 million; R&D expense rises to USD 10.28 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2632297640","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632297640?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:02","pubTimestamp":1777669336,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences posted a net loss of USD 18.4 million for fiscal 2025.Revenue remained at no revenue from product sales.Research and development expense climbed to USD 10.28 million.January 2026 best-efforts registered direct offering raised gross proceeds of USD 8.8 million, with net proceeds of about USD 8.6 million earmarked to complete Phase 2a trials in na-SPMS and MSA through topline readouts.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL17bK7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632662525","title":"Tiziana Life Sciences delays filing annual Form 20-F for 2025 fiscal year","url":"https://stock-news.laohu8.com/highlight/detail?id=2632662525","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632662525?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:39","pubTimestamp":1777585194,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences filed notice that its annual report on Form 20-F for fiscal year ended Dec. 31, 2025 will be late.Company expects to file Form 20-F within 15 calendar days after original due date.Delay was attributed to time constraints tied to compiling, distributing, and reviewing required disclosures.Filing stated no significant change in results of operations is expected versus prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 30, 2026, and is solely responsible for the information c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3qdRTl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290548","title":"Tiziana Life announces publication of preclinical data in bioRxiv preprint","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290548?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:01","pubTimestamp":1776340884,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (TLSA) announces the publication of positive preclinical data in a bioRxiv preprint. The study, titled “Intranasal Anti-CD3 A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-publication-of-preclinical-data-in-biorxiv-preprint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tiziana-life-announces-publication-of-preclinical-data-in-biorxiv-preprint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627229422","title":"Tiziana reports preclinical data showing intranasal foralumab eases Long COVID brain inflammation in mice","url":"https://stock-news.laohu8.com/highlight/detail?id=2627229422","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627229422?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:00","pubTimestamp":1776337241,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences disclosed positive preclinical results for intranasal foralumab in a bioRxiv preprint published April 16, 2026; findings have already been presented in that publication.Mouse-model study showed treatment reduced Long COVID-linked neuroinflammation, supported brain repair processes, and improved cognitive function.Data also indicated Long COVID patients with neurological symptoms had lower circulating regulatory T-cell levels, supporting clinical relevance of immune-modulating approach.Tiziana positioned results as mechanistic support for ongoing intranasal foralumab development across multiple neuroinflammatory and neurodegenerative programs.Company noted prior expanded-access use in non-active secondary progressive multiple sclerosis showed favorable safety with signals of clinical benefit.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9W23dk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BK4112","LU2095319765.USD","TLSA","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","LU2210150020.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627294212","title":"Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-Cd3 Antibody Attenuates Long Covid Neuroinflammation and Improves Cognitive Function","url":"https://stock-news.laohu8.com/highlight/detail?id=2627294212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627294212?lang=en_us&edition=fundamental","pubTime":"2026-04-16 19:00","pubTimestamp":1776337200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA7R85QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TLSA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627410793","title":"Tiziana presents Phase 2a intranasal foralumab MSA trial poster at World Parkinson Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2627410793","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627410793?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:01","pubTimestamp":1776164494,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences flagged a late-breaking poster on its Phase 2a trial of intranasal foralumab in Multiple System Atrophy , scheduled for presentation at 7th World Parkinson Congress on May 24-27, 2026.Poster will outline trial design and rationale, not clinical results.Study tests whether intranasal foralumab can reduce neuroinflammation tied to disease progression in MSA, condition with no approved disease-modifying therapy.Open-label Phase 2a trial plans to enroll up to 10 patients for 6 months of dosing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL4NPVyf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624971945","title":"Tiziana says preclinical data show intranasal foralumab reverses brain aging, boosts cognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2624971945","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624971945?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:00","pubTimestamp":1775041231,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences reported positive preclinical results for intranasal foralumab in an aging model, positioning nasal anti-CD3 as potential approach for age-related cognitive impairment.Data were presented in April 2026, showing treatment reversed key aspects of brain aging and improved cognition.Study indicated reduced neuroinflammation tied to microglial activation, supporting a mechanism aimed at lowering inflammation-linked cognitive decline.Results also pointed to increased hippocampal neurogenesis and reduced cellular senescence, suggesting potential to support brain repair processes.Tiziana highlighted ongoing clinical programs for intranasal foralumab across several neurodegenerative indications while expanding preclinical work in aging.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2WqtzJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLSA","SG9999014021.USD","IE00BKPKM429.USD","BK4588","LU2210149790.SGD","NDAQ","SG9999014039.USD","LU0314104364.USD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4139","BK4112","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":-0.1129},{"period":"1month","weight":-0.2667},{"period":"3month","weight":-0.0984},{"period":"6month","weight":-0.382},{"period":"1year","weight":-0.2254},{"period":"ytd","weight":-0.2617}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.062066},{"month":2,"riseRate":0.125,"avgChangeRate":0.000048},{"month":3,"riseRate":0.375,"avgChangeRate":0.130911},{"month":4,"riseRate":0.625,"avgChangeRate":0.144279},{"month":5,"riseRate":0.5,"avgChangeRate":0.187138},{"month":6,"riseRate":0.375,"avgChangeRate":-0.02778},{"month":7,"riseRate":0.428571,"avgChangeRate":0.326851},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.143149},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.016089},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.076885},{"month":11,"riseRate":0,"avgChangeRate":-0.127748},{"month":12,"riseRate":0,"avgChangeRate":-0.132657}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC","securityTypeName":"DR","adrRate":"1:2"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction